4-(5-chloro-2-methoxy-benzyl)-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester | 1003567-08-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(5-chloro-2-methoxy-benzyl)-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 4-(5-chloro-2-methoxybenzyl)-4-hydroxypiperidine-1-carboxylate；tert-butyl 4-[(5-chloro-2-methoxyphenyl)methyl]-4-hydroxypiperidine-1-carboxylate
• CAS: 1003567-08-5
• 化学式: C₁₈H₂₆ClNO₄
• 分子量: 355.862
• InChiKey: IQVIQCWTEUGEPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(5-chloro-2-methoxy-benzyl)-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester 在 氢溴酸 、 溶剂黄146 作用下， 以 水 为溶剂， 反应 9.33h， 以79%的产率得到5-chloro-3H-spiro[1-benzofuran-2,4'-piperidine] hydrobromic acid salt
  参考文献：
  名称：

  [EN] A PROCESS FOR THE PREPARATION OF INTERMEDIATES AND THEIR US IN THE SYNTHESIS OF SPIROPIPERIDINE COMPOUNDS
  [FR] PROCÉDÉ POUR LA PRÉPARATION DE PRODUITS INTERMÉDIAIRES ET UTILISATION DE CEUX-CI DANS LA SYNTHÈSE DE COMPOSÉS DE SPIROPIPÉRIDINE

  摘要：

  本发明涉及一种制备式I化合物的新工艺，特别是化合物2-{2-氯-5-{[(2S)-3-(5-氯-1'H,3H-螺[1-苯并呋喃-2,4'-哌啶]-1'-基)-2-羟基丙基]氧基}-4-5-[(甲氨基)羰基]苯氧基}-2-甲基丙酸以及用于其制备的新中间体。

  公开号：

  WO2009011653A1
• 作为产物：
  描述：

  1-噁-6-氮杂螺[2.5]辛烷-6-羧酸-1,1-二甲基乙酯 在 异丙基氯化镁 、 copper(I) bromide dimethylsulfide complex 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 8.17h， 以82%的产率得到4-(5-chloro-2-methoxy-benzyl)-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  WO2008/10765

  摘要：

  公开号：

文献信息

• [EN] SPLROPIPERIDINE COMPOUNDS, A PROCESS OF THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THE TREATMENT OF AIRWAY DISEASES, INFLAMMATORY DISEASES, COPD OR ASTHMA<br/>[FR] COMPOSÉS SPIROPIPÉRIDINES, LEUR PROCÉDÉ DE PRÉPARATION, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, ET LEUR UTILISATION DANS LE TRAITEMENT DES MALADIES DES VOIES AÉRIENNES, DES MALADIES INFLAMMATOIRES, DE LA BRONCHOPNEUMOPATHIE CHRONIQUE OBSTRUCTIVE
  申请人：ASTRAZENECA AB

  公开号：WO2009011655A1

  公开（公告）日：2009-01-22

  The present invention relates to new polymorphs of compounds 2-2-Chloro-5-[(2S)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4- [(methylamino)carbonyl]phenoxy}-2-methylpropanoic acid, and the hydrochloride and sodium hydroxide salts thereof,and compound 2-2-Chloro-5-[(2R)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4- [(methylamino)carbonyl]phenoxy}-2-methylpropanoic acid. The invention further relates to pharmaceutical composition containing said compounds and to the use of said compounds in therapy. The present invention also relates to processes for the preparation of said compounds.

  本发明涉及化合物2-2-氯-5-[(2S)-3-(5-氯-1'H,3H-螺[1-苯并呋喃-2,4'-哌啶]-1'-基)-2-羟基丙基]氧基}-4-[(甲基氨基)羰基]苯氧基}-2-甲基丙酸的新多晶形态，以及其盐包括盐酸盐和氢氧化钠盐，以及化合物2-2-氯-5-[(2R)-3-(5-氯-1'H,3H-螺[1-苯并呋喃-2,4'-哌啶]-1'-基)-2-羟基丙基]氧基}-4-[(甲基氨基)羰基]苯氧基}-2-甲基丙酸。该发明还涉及含有上述化合物的药物组合物以及上述化合物在治疗中的用途。本发明还涉及制备上述化合物的方法。
• Novel Compounds 243
  申请人：Gibson Scott

  公开号：US20080167332A1

  公开（公告）日：2008-07-10

  Compounds of formula (I) wherein R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 10 are as defined in the specification, are described. The present invention also relates to pharmaceutical composition comprising said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof. Beside, the invention relates to salts and polymorphic forms of the new compounds as well as the preparation thereof.

  本发明描述了式(I)的化合物，其中R1、R3、R4、R5、R6、R7和R10如说明书中所定义。本发明还涉及包含所述化合物的制药组合物以及所述化合物在治疗中的使用。本发明还涉及制备所述化合物的过程以及制备所述化合物有用的新中间体。此外，本发明还涉及新化合物的盐和多晶形式，以及其制备。
• Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity
  申请人：Eriksson Tomas

  公开号：US20090176815A1

  公开（公告）日：2009-07-09

  Compounds of formula (I) wherein R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 10 are as defined in the specification, are described. The present invention also relates to pharmaceutical composition comprising said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof. Beside, the invention relates to salts and polymorphic forms of the new compounds as well as the preparation thereof.

  本发明描述了式(I)的化合物，其中R1、R3、R4、R5、R6、R7和R10如规范中所定义。本发明还涉及包含所述化合物的制药组合物以及在治疗中使用所述化合物的用途。本发明还涉及制备所述化合物的过程以及在制备中有用的新中间体。此外，本发明还涉及所述新化合物的盐和多晶形式以及其制备。
• NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：AstraZeneca AB

  公开号：EP2069355A1

  公开（公告）日：2009-06-17
• [EN] NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：ASTRAZENECA AB

  公开号：WO2008010765A1

  公开（公告）日：2008-01-24

  [EN] Compounds of formula (I) wherein R¹, R³, R⁴, R⁵, R⁶, R⁷, and R¹⁰ are as defined in the specification, are described. The present invention also relates to pharmaceutical composition comprising said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof. Beside, the invention relates to salts and polymorphic forms of the new compounds as well as the preparation thereof.
  [FR] L'invention concerne des composés de formule (I) dans laquelle R¹, R³, R⁴, R⁵, R⁶, R⁷ et R¹⁰ sont tels que définis dans la description. La présente invention concerne également une composition pharmaceutique comprenant ces composés, ainsi que l'utilisation de ces composés en thérapie. La présente invention concerne, en outre, des procédés de préparation de ces composés et de nouveaux intermédiaires utiles dans leur préparation. De plus, l'invention concerne des sels et des formes polymorphes des nouveaux composés, ainsi que leur préparation.